Table 1Mutational patterns selected by NRTI monotherapies

NRTIMutations most frequently selectedReferences
ZDV, d4TTAMs
pathway 1: M41L, L210W, T215Y (2/3 of cases)
pathway 2: D67N, K70R, T215F, K219Q/E (1/3 of cases
[46]
ddIL74V[7]
3TC, FTCM184V[9]
ABCL74V and M184V[12]
TDFK65R[14]

ABC, abacavir; ddI, didanosine; d4T, stavudine; FTC, emtricitabine; NRTI, nucleoside reverse transcriptase inhibitor; TAMs, thymidine analogue mutations; TDF, tenofovir; 3TC, lamivudine; ZDV, zidovudine.

From: Chapter 1, Resistance to nucleoside reverse transcriptase inhibitors

Cover of Antiretroviral Resistance in Clinical Practice
Antiretroviral Resistance in Clinical Practice.
Geretti AM, editor.
London: Mediscript; 2006.
Copyright © 2006, Mediscript.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.